# Supplemental Table S3.Remission rates in patients by treatment with venetoclax and azacitidine or azacitidine alone

|  |  |  |
| --- | --- | --- |
|  | **Venetoclax + Azacitidine** | **Azacitidine** |
|  | ***FLT3-ITD*** | ***FLT3-TKD*** | ***FLT3-ITD* and *NPM1*** | ***FLT3-ITD and NPM1wt*** | ***FLT3-ITD*** | ***FLT3-TKD*** | ***FLT3-ITD and NPM1*** | ***FLT3-ITD and NPM1wt*** |
| **(n=30)** | **(n=13)** | **(n=10)** | **(n=19)** | **(n=13)** | **(n=10)** | **(n=5)** | **(n=8)** |
| CR rate | 9 (30.0) | 7 (53.8) | 3 (30.0) | 6 (31.6) | 2 (15.4) | 2 (20.0) | 1 (20.0) | 1 (12.5) |
| CR + CRi | 19 (63.3) | 10 (76.9) | 7 (70.0) | 11 (57.9) | 6 (46.2) | 3 (30.0) | 3 (60.0) | 3 (37.5) |
| Median DoR for CR+CRi, months (95% CI)  | 17.3 (4.6 ─ NE) | 15.9 (2.8 ─ NE) | NR (4.6 ─ NE) | 10.1 (1.8 ─ NE) | 8.7 (1.0, NE) | 15.9 (5.0 ─ NE) | 3.5 (1.0 ─ NE) | 13.8 (3.5 ─ NE) |

Abbreviations: CR, complete remission; CRi, CR+ incomplete hematological recovery; CI, confidence interval; NE, not evaluable;

NR, Not reached